FindTrial
Sign In

Development of a Recurrence Risk Prediction Model for Type 1 Gastric Neuroendocrine Tumors and an AI-Assisted Gastroscopic Efficacy Evaluation System Based on an Ambidirectional Cohort Study

Development of a Recurrence Risk Prediction Model for Type 1 Gastric Neuroendocrine Tumors and an AI-Assisted Gastroscopic Efficacy Evaluation System Based on an Ambidirectional Cohort Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118121
Enrollment
Unknown
Registered
2026-02-02
Start date
2026-02-15
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 neuroendocrine tumors (NETs)

Interventions

Unexposed group:None
Exposed group:None

Sponsors

China-Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Patients diagnosed with type 1 g-NETs (gastric neuroendocrine tumors) at the China-Japan Friendship Hospital between January 2010 and December 2026; 2.Availability of at least two gastroscopy examinations with traceable images for review; 3.Provision of signed informed consent forms.

Exclusion criteria

Exclusion criteria: 1.Critical follow-up data is missing, making effective assessment of type 1 g-NETs progression unfeasible.

Design outcomes

Primary

MeasureTime frame
Hazard ratio of tumor recurrence effect;Relative risk of tumor recurrence;—

Secondary

MeasureTime frame
Cumulative tumor recurrence rate;—

Countries

China

Contacts

Public ContactChao Deng

China-Japan Friendship Hospital

superaifer@126.com+86 10 84205733

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026